AOD-9604 (HGH Frag 176-191)
5mg
❄️Lyophilized powder (not reconstituted)
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €44.96 |
| 11 - 20 | 15% | €42.46 |
| 21+ | 20% | €39.96 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €49.95
AOD-9604 is supplied as a catalogued research material in 5 mg.
AOD-9604 is a defined 16-residue disulfide peptide, more precisely Tyr-hGH(177–191). The common “HGH Fragment 176–191” label should not be treated as proof that the material is the unmodified native fragment [1,2].
Chemical properties and registry information
| Property | Value |
|---|---|
| Name and synonyms | AOD-9604; Tyr-hGH(177–191); commonly marketed as HGH Fragment 176–191 |
| Material category | Synthetic cyclic disulfide analogue of a C-terminal human growth-hormone fragment; research peptide |
| Sequence or structural definition | H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH; YLRIVQCRSVEGSCGF |
| Molecular formula | C78H123N23O23S2 for the free cyclic peptide; salts and solvates differ. |
| Average molecular mass | 1815.1 g/mol average mass for the free cyclic peptide. |
| CAS Registry Number | 221231-10-3 for the free cyclic peptide, conditional on exact-form confirmation. |
| PubChem CID | CID 71300630 for the free cyclic peptide, conditional on exact-form confirmation. |
| Structural features | 16 residues with a Cys7–Cys14 intramolecular disulfide; N-terminal Tyr replaces the Phe present in native hGH(176–191). |
| Appearance | White to off-white lyophilised powder. |
| Solubility | Highly hydrophobic. Reconstitute with 0.6% acetic acid water; not readily soluble in plain bacteriostatic or sterile water. |
| Physical form | Catalogue vial; the exact physical state, salt or counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
| Catalogue presentations | 5 mg |
| Batch identity and quality documentation | Lot-specific identity and available analytical reports must be verified against the CoA entry associated with the exact product size and batch. |
Registry values apply only to the matching sequence or structure and exact material form. Confirm terminal modifications, conjugation, salt or counter-ion and hydration against the batch CoA and SDS; batch records take precedence over literature identifiers.
Research background and published evidence
Published research
Published work has examined AOD-9604 and related C-terminal hGH fragments in structural, metabolic and analytical research models [2,3].
Current scientific understanding
The FDA review identified limited human evidence, no human pharmacokinetic data and no established clinical efficacy. Those publications do not authenticate this catalogue batch or support human use [2].
AOD-9604, native hGH(176–191), acetate salts and other fragment analogues are analytically distinct materials.
Technical comparison
| Aspect | This catalogue material | Comparator |
|---|---|---|
| Identity | AOD-9604: cyclic Tyr-hGH(177–191), conditional on batch confirmation | Native hGH(176–191) C-terminal fragment |
| Structural distinction | Tyr at the N terminus and a defined Cys7–Cys14 disulfide | Phe at the corresponding N-terminal position of the native 176–191 fragment |
| Analytical implication | Confirm intact mass, disulfide connectivity, termini and counter-ion | Sequence-specific analysis must distinguish the N-terminal Phe/Tyr substitution |
Quality and testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory handling and storage
Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment and waste disposal should follow the applicable SDS and the institution's approved procedures.
Regulatory and legal status
| Research-use notice | This material is supplied exclusively for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements. |
Sources and references
- [1] PubChem. AOD-9604, CID 71300630.
- [2] U.S. FDA. Pharmacy Compounding Advisory Committee review of AOD-9604.
- [3] Heffernan et al. Research on the C-terminal human growth-hormone fragment and AOD-9604.
Frequently Asked Questions
Do the CAS number and PubChem CID apply to every batch form?
Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.
What does an analytical purity result mean?
It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.
How should the material be stored and handled?
Follow the exact label, batch CoA and SDS together with the institution's risk assessment. Use only storage and stability information linked to the exact material form and batch.